Want to see HK:2617 full AI Analyst Report?
Top Page
TransThera Sciences (Nanjing). Inc.
(2617)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$9.00
â–¼(-15.57% Downside)
Action:Reiterated
Date:07/03/26
The score is held down primarily by minimal/zero recent revenue, large ongoing losses, and substantial negative operating/free cash flow, which imply continued reliance on external funding. Technicals reinforce the risk with a pronounced downtrend and weak momentum. The key offset is a conservatively financed balance sheet with very low leverage, which reduces near-term solvency pressure despite ongoing burn.
Positive Factors
Low financial leverage
Very low debt relative to equity limits refinancing and interest-rate exposure, giving the company greater financial flexibility while it develops its pipeline. This conservative capital structure provides a stronger buffer against operating volatility than a highly leveraged balance sheet would.
Negative Factors
No recent revenue base
Zero revenue in the two latest annual periods shows that the company has not yet established a commercial operating base. Without product sales, funding for research, clinical development, and other activities must continue before recurring revenue can support the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low debt relative to equity limits refinancing and interest-rate exposure, giving the company greater financial flexibility while it develops its pipeline. This conservative capital structure provides a stronger buffer against operating volatility than a highly leveraged balance sheet would.
Read all positive factors
TransThera Sciences (Nanjing). Inc. (2617) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.93B
Dividend YieldN/A
Average Volume (3M)9.40M
Price to Earnings (P/E)―
Beta (1Y)3.20
Revenue GrowthN/A
EPS Growth-13.84%
CountryHK
Employees132
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding312,687,680
10 Day Avg. Volume3,284,750
30 Day Avg. Volume9,396,120
Financial Highlights & Ratios
PEG Ratio-13.39
Price to Book (P/B)96.58
Price to Sales (P/S)0.00
P/FCF Ratio-158.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TransThera Sciences (Nanjing). Inc. Business Overview & Revenue Model
Company Description
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420),...
TransThera Sciences (Nanjing). Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.97M | 0.00 | 0.00 | 1.18M | 124.00K | 61.76M |
| Gross Profit | 30.68M | 0.00 | 0.00 | 1.18M | 124.00K | 0.00 |
| EBITDA | -267.60M | -290.82M | -267.97M | -416.80M | -346.90K | -39.27M |
| Net Income | -268.29M | -295.96M | -274.61M | -344.12M | -250.04M | -80.72M |
Balance Sheet | ||||||
| Total Assets | 987.24M | 545.91M | 629.60M | 887.09M | 1.35B | 344.94M |
| Cash, Cash Equivalents and Short-Term Investments | 925.22M | 489.14M | 572.53M | 838.17M | 1.11B | 279.34M |
| Total Debt | 5.61M | 1.65M | 4.37M | 4.81M | 3.04M | 490.74M |
| Total Liabilities | 109.26M | 129.53M | 104.57M | 103.91M | 111.04M | 578.87M |
| Stockholders Equity | 877.99M | 416.38M | 525.03M | 783.18M | 1.24B | -233.94M |
Cash Flow | ||||||
| Free Cash Flow | -144.55M | -253.68M | -271.95M | -331.12M | -244.00M | -76.61M |
| Operating Cash Flow | -144.47M | -253.51M | -271.18M | -319.33M | -241.94M | -66.68M |
| Investing Cash Flow | 108.03M | -68.00M | 348.42M | -186.94M | 26.98M | -195.84M |
| Financing Cash Flow | 1.55M | 169.00M | -4.87M | 15.76M | 240.45M | 311.48M |
TransThera Sciences (Nanjing). Inc. Technical Analysis
Negative
10.66
Price Trends
10.37
Negative
24.41
Negative
65.25
Negative
Market Momentum
-0.57
Negative
32.11
Neutral
14.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2617, the sentiment is Negative. The current price of 10.66 is above the 20-day moving average (MA) of 10.05, above the 50-day MA of 10.37, and below the 200-day MA of 65.25, indicating a bearish trend. The MACD of -0.57 indicates Negative momentum. The RSI at 32.11 is Neutral, neither overbought nor oversold. The STOCH value of 14.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2617.
TransThera Sciences (Nanjing). Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$62.73B | 11.04 | 128.12% | ― | 305.94% | ― | |
64 Neutral | HK$34.35B | 33.83 | 20.41% | ― | 32.63% | 8.87% | |
62 Neutral | HK$70.85B | -13.82 | -16.23% | 0.35% | 53.48% | -120.02% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$21.51B | -13.86 | -27.40% | ― | 5.38% | 16.86% | |
46 Neutral | HK$32.15B | -72.62 | -7.32% | ― | 34.83% | 58.94% | |
44 Neutral | HK$2.93B | -7.77 | -40.84% | ― | ― | -13.84% |
* General Sector Average
HK:2617
TransThera Sciences (Nanjing). Inc.
9.38
-405.63
-97.74%
HK:1548
Genscript Biotech
32.36
15.31
89.79%
HK:9688
Zai Lab Ltd
18.94
-6.08
-24.30%
HK:9995
RemeGen Co. Ltd. Class H
73.75
-36.65
-33.20%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
16.60
-16.30
-49.54%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
63.00
-16.65
-20.90%
TransThera Sciences (Nanjing). Inc. Corporate Events
TransThera Sciences Narrows Interim Loss as Revenue Emerges Amid Rising R&D Spend
Aug 26, 2026
TransThera Sciences (Nanjing), Inc. reported its unaudited interim results for the six months ended 30 June 2026, posting revenue of RMB35.46 million versus no revenue a year earlier and a gross profit of the same amount as no cost of sales was re...
TransThera Sciences Sets Board Meeting to Review Interim Results and Potential Dividend
Aug 14, 2026
TransThera Sciences (Nanjing), Inc. has scheduled a board meeting for 26 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also consider the declaration and payment o...
TransThera Wins First China Approval for Yochanra in Advanced Cholangiocarcinoma
Aug 6, 2026
TransThera Sciences (Nanjing) has secured conditional marketing approval in China for its Class 1 new drug Yochanra, or tinengotinib tablets, to treat adult patients with unresectable advanced or metastatic cholangiocarcinoma harboring FGFR2 fusio...
TransThera Grants Over 5.2 Million H-Share Awards and Options to Staff
Jul 24, 2026
TransThera Sciences (Nanjing), Inc. has granted a total of 2,816,900 share awards and 2,442,000 share options, representing 5,258,900 H shares, to 67 employees under its H Share Award Scheme, including allocations to directors Frank Wu and Wu Di. ...
TransThera Wins NMPA Nod for Phase II Lung Cancer Trial of TT-00973 Combo
Jul 10, 2026
TransThera Sciences (Nanjing), Inc. has received approval from China’s National Medical Products Administration to initiate a multi-center, open-label Phase II clinical trial of its novel AXL/FLT3 inhibitor TT-00973 in combination with firmo...
TransThera Completes Global Phase III Enrollment for Tinengotinib in Advanced Cholangiocarcinoma
Jul 1, 2026
TransThera Sciences has completed patient enrollment in a global multicenter, randomized Phase III trial of its lead drug tinengotinib as an oral monotherapy for advanced cholangiocarcinoma with FGFR gene aberrations that has relapsed or become re...
TransThera Wins China Nod for Phase II Trial of Novel BTK Inhibitor in Mantle Cell Lymphoma
Jul 1, 2026
TransThera Sciences (Nanjing), Inc. has received approval from China’s National Medical Products Administration to initiate a Phase II trial of its novel BTK inhibitor TT-01488 in combination with an anti-CD20 monoclonal antibody for mantle ...
TransThera Sciences to Launch Up to RMB100 Million H-Share Buyback
Jun 28, 2026
TransThera Sciences (Nanjing), Inc. has announced a plan to repurchase up to RMB100 million worth of its H shares on the open market under a general mandate granted by shareholders at the 18 June 2026 annual general meeting. The repurchase window ...
TransThera Sciences Sets Formal Terms for Audit Committee to Strengthen Governance
Jun 18, 2026
TransThera Sciences (Nanjing), Inc. has formally established detailed terms of reference for its board-level Audit Committee to strengthen oversight of financial reporting, internal controls, and internal and external audit functions, in line with...
TransThera Sets Formal Nomination Committee Rules to Strengthen Board Governance
Jun 18, 2026
TransThera Sciences (Nanjing), Inc. has formalized detailed terms of reference for its Board Nomination Committee to strengthen director and senior management appointments and improve overall board composition. The committee is mandated to operate...
TransThera Sets Board Committee Rules to Tighten Pay and Performance Oversight
Jun 18, 2026
TransThera Sciences (Nanjing), Inc. has adopted detailed terms of reference for a Board-level Remuneration and Appraisal Committee to strengthen its corporate governance. The committee is structured as an independent-focused body responsible for o...
TransThera Sets Up Strategy Committee to Tighten Governance and Guide Long-Term Investments
Jun 18, 2026
TransThera Sciences (Nanjing), Inc. has established a Strategy Committee under its board of directors to guide long-term development and major investment decisions, aiming to strengthen core competitiveness and improve scientific decision-making. ...
TransThera Wins Shareholder Approval for New H Share Award Scheme
Jun 18, 2026
TransThera Sciences (Nanjing), Inc. reported that all resolutions proposed at its extraordinary general meeting on 18 June 2026 were approved by shareholders through a poll, with all directors in attendance and no shareholders required to abstain ...
TransThera Shareholders Back Governance Revamp and Board Changes at 2026 AGM
Jun 18, 2026
TransThera Sciences (Nanjing), Inc. reported that shareholders approved all resolutions at its 18 June 2026 annual general meeting, including the 2025 board and supervisory committee reports, audited financial statements, the annual report, and a ...
TransThera Sciences Outlines Board and Committee Structure in Governance Update
Jun 18, 2026
TransThera Sciences (Nanjing), Inc. has disclosed the current composition of its board of directors, comprising executive, non-executive, and independent non-executive directors, as part of a corporate governance update. The company also detailed ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.